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Abstract
Background: Breast cancer cells with CD44+/CD24- cell surface marker expression profile are proposed as cancer
stem cells (CSCs). Normal breast epithelial cells that are CD44+/CD24- express higher levels of stem/progenitor cell
associated genes. We, amongst others, have shown that cancer cells that have undergone epithelial to
mesenchymal transition (EMT) display the CD44+/CD24- phenotype. However, whether all genes that induce EMT
confer the CD44+/CD24- phenotype is unknown. We hypothesized that only a subset of genes associated with
EMT generates CD44+/CD24- cells.
Methods: MCF-10A breast epithelial cells, a subpopulation of which spontaneously acquire the CD44+/CD24-
phenotype, were used to identify genes that are differentially expressed in CD44+/CD24- and CD44-/CD24+ cells.
Ingenuity pathway analysis was performed to identify signaling networks that linked differentially expressed genes.
Two EMT-associated genes elevated in CD44+/CD24- cells, SLUG and Gli-2, were overexpressed in the CD44-/CD24
+ subpopulation of MCF-10A cells and MCF-7 cells, which are CD44-/CD24+. Flow cytometry and mammosphere
assays were used to assess cell surface markers and stem cell-like properties, respectively.
Results: Two thousand thirty five genes were differentially expressed (p < 0.001, fold change ≥ 2) between the
CD44+/CD24- and CD44-/CD24+ subpopulations of MCF-10A. Thirty-two EMT-associated genes including SLUG, Gli-
2, ZEB-1, and ZEB-2 were expressed at higher levels in CD44+/CD24- cells. These EMT-associated genes participate
in signaling networks comprising TGFb, NF-B, and human chorionic gonadotropin. Treatment with tumor necrosis
factor (TNF), which induces NF-B and represses E-cadherin, or overexpression of SLUG in CD44-/CD24+ MCF-10A
cells, gave rise to a subpopulation of CD44+/CD24- cells. Overexpression of constitutively active p65 subunit of NF-
B in MCF-10A resulted in a dramatic shift to the CD44+/CD24+ phenotype. SLUG overexpression in MCF-7 cells
generated CD44+/CD24+ cells with enhanced mammosphere forming ability. In contrast, Gli-2 failed to alter CD44
and CD24 expression.
Conclusions: EMT-mediated generation of CD44+/CD24- or CD44+/CD24+ cells depends on the genes that
induce or are associated with EMT. Our studies reveal a role for TNF in altering the phenotype of breast CSC.
Additionally, the CD44+/CD24+ phenotype, in the context of SLUG overexpression, can be associated with breast
CSC “stemness” behavior based on mammosphere forming ability.
Background
Cancer stem cell theory proposes that cancers may arise
from malignant transformation of normal stem/progeni-
tor cells. Alternatively, cellular plasticity and/or the
tumor microenvironment may permit mature/differen-
tiated cells to acquire a stem/progenitor phenotype
[1-6]. Tumorigenic stem/progenitor cells have been
documented in hematologic malignancies as well as in
solid tumors, although correct terminology for these
cells (cancer stem cells versus tumor initiating cells) is
still a matter of debate [7-9]. Several studies implicate a
subset of human breast cancer cells with an enhanced
ability to form tumors in immunocompromised mice
[10,11]. This subpopulation of cells also demonstrated
the capacity for self-renewal and generation of hetero-
geneous progeny. At present, two distinct cell types
* Correspondence: hnakshat@iupui.edu
1Department of Surgery, Indiana University School of Medicine, West Walnut
Street, Indianapolis, IN 46202, USA
Full list of author information is available at the end of the article
Bhat-Nakshatri et al. BMC Cancer 2010, 10:411
http://www.biomedcentral.com/1471-2407/10/411
© 2010 Bhat-Nakshatri et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.have been described as CSCs for breast cancer. Cancer
cells that display the cell surface marker profile of
CD44
+/CD24
-/Lineage
- were the first described tumori-
genic progenitor cell types for breast cancer [10]. NOD/
SCID mice implanted with as few as 200 CD44+/CD24-
cells form tumors. In addition, disseminated cancer cells
in bone marrow with CD44+/CD24- phenotype have
been identified in patients, although the prognostic rele-
vance of this is as yet unclear [12-14]. Signaling path-
ways implicated in self-renewal and survival of normal
organ-specific stem cells and embryonic stem cells, such
as Hedgehog, Notch and Wnt/b-catenin, may be
involved in maintaining “stemness” of CD44+/CD24-/
lineage- cells [15-18]. The gene expression pattern of
CD44+/CD24- CSCs is more similar to normal
CD44+/CD24- breast epithelial cells than to CD44-/
CD24+ cells isolated from tumors [19]. Recent studies
have demonstrated enrichment of CSC gene expression
signature in breast cancers that are classified as Clau-
din-low subtype [20]. We demonstrated that breast can-
cer cells with CD44+/CD24- phenotype express elevated
levels of invasion-associated genes and are invasive but
this phenotype is not a requisite for homing and growth
at sites of metastasis [21]. In subsequent studies, normal
and cancerous breast epithelial cells expressing higher
levels of aldehyde dehydrogenase 1 (ALDH1) were
described as normal and tumorigenic stem/progenitor
cells [22]. Functional assays revealed ALDEFLUOR-posi-
tive cells (aldefluor staining provides indirect estimation
of all ALDHs in cells) to be highly tumorigenic relative
to ALDEFLUOR-negative cells. Moreover, the most
tumorigenic phenotype identified was ALDEFLUOR
+/CD44+/CD24- cells [22]. Additional refinement of the
breast cancer stem cell phenotype has been described
recently [23].
During our analysis of breast cancer cell lines for sub-
populations with the CD44+/CD24- phenotype, we
observed that almost all cell lines with a CD44+/CD24-
subpopulation were basal breast cancer cells that had
undergone epithelial to mesenchymal transition (EMT)
[21]. Others have also reported enrichment of cells with
the CD44+/CD24- phenotype in basal-like breast tumors
[14]. EMT is a developmental process during which
epithelial cells acquire a fibroblastoid and invasive phe-
notype, down-regulate epithelial-specific proteins, and
induce various mesenchymal proteins [24]. There are
specific changes in the gene expression profile during
EMT. These include expression of vimentin and loss of
E-cadherin expression; the change in expression of both
of these markers has been associated with poor prog-
nosis in breast cancer [25-27]. Activation of oncogenic
and receptor tyrosine kinase pathways such as Ras and
Src, or signaling through transforming growth factor
beta (TGFb), hepatocyte growth factor (HGF) and
platelet derived growth factor (PDGF) can trigger EMT
[24,28]. These signaling pathways induce the expression
of the SNAIL family of transcription repressors, which
reduce E-cadherin expression [29]. SNAIL family mem-
bers involved in initiation and/or maintenance of EMT
include SNAIL-1 [30,31], Snai2/SLUG [32,33], E12/E47
[34], ZEB-1/ZFHX1A [35], ZEB-2/ZFXH1B/Smad-Inter-
acting Protein (SIP1) and TWIST [36].
Recent studies have shown that some members of the
SNAIL family confer an EMT phenotype to breast
epithelial cells, which correlates with cells changing phe-
notype from CD44-/CD24+ to CD44+/CD24- [37,38].
However, it is not known whether all genes that induce
EMT confer a CD44+/CD24- phenotype to breast
epithelial cells or if all breast epithelial subtypes are
equally susceptible to such EMT-mediated phenotypic
change.
In this study we have utilized the basal cell phenotype
MCF-10A breast epithelial cell line [39] to study the
association between CD44+/CD24- and the EMT phe-
notype. Although the majority of MCF-10A cells are
CD44-/CD24+ or CD44+/CD24+, a fraction of these
cells are CD44+/CD24-. Gene expression analysis of
CD44+/CD24- cells compared to CD44-/CD24+ cells
revealed increased expression of 32 EMT associated
genes including SLUG, ZEB-1, ZEB-2, Hedgehog signal-
ing associated gene Gli-2, and the metastasis-associated
gene SATB-1. Transgenic overexpression studies showed
that only SLUG had the capacity to alter the phenotype
of CD44-/CD24+ MCF-10A cells to induce a subpopula-
tion of CD44+/CD24- cells. However, transgenic overex-
pression of SLUG in the luminal type breast cancer cell
line, MCF-7, generated cells with a CD44+/CD24+ phe-
notype, suggesting that basal cell types but not luminal
cell types are susceptible to EMT associated acquisition
of CD44+/CD24- phenotype. Additionally, only specific
EMT associated genes induced a CD44+/CD24- pheno-
type in MCF-10A cells. For example, overexpression of
the NF-B subunit of p65 upregulates expression of
ZEB-1 and ZEB-2 genes [40], and this resulted an
increase in the percent of CD44+/CD24+ MCF-10A
cells but not the percent of CD44+/CD24- cells.
Methods
Cell lines, plasmids, reagents, and retroviral vector
transduction
MCF-7, MCF-10A and Ampho-phoenix cells were main-
tained as described previously [40,41]. All experiments
were done with cells of similar confluence, except in
case of TNF treated cells, which were always less dense
compared to control cells at the time of harvest. MCF-
10Ap65 cells have been described previously [40]. The
bicistronic retrovirus vector pcQXIP (Clontech, CA) was
used to generate MCF-10A cells overexpressing Ras
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g i f t sf r o mD r s .E .R .F e a r o n( U n i v e r s i t yo fM i c h i g a n )
[33], and H. Sasaki (Osaka University) [42], respectively.
SATB-1 cDNA was purchased from Origene Technolo-
gies, Inc (Rockville, MD). The SLUG and SATB-1
cDNA was cloned into pcQXIN to generate supernatant
containing retroviral vector. Packaging of retroviral vec-
tor particles, transduction, and selection of transduced
cells have been described previously [40,41]. Tumor
necrosis factor (TNF) was purchased from R&D Systems
(Minneapolis, MN, USA).
Matrigel and Mammosphere assays
Matrigel assay was performed as described previously
[40]. Briefly, cells were plated on matrigel in eight-well
chamber slides for 10 days. Matrigel was fixed overnight
in formalin and embedded on histogel as described pre-
viously [40]. For the mammosphere assay, one hundred
thousand cells were plated on ultralow adherent plates
in serum free media with methylcellulose and supple-
ments as described previously [38]. After 10 days of cul-
turing, mammospheres in 10 independent microscopic
fields were enumerated. Alternatively, media with mam-
mospheres were collected, washed in PBS, resuspended
in two ml PBS and large colonies were counted using a
hemocytometer and expressed as number of mammo-
spheres per 100,000 cells.
Electrophoretic mobility shift assay (EMSA)
Whole cell lysates prepared from MCF-10A, CD44
+/CD24-, and CD44-/CD24+ cells were subjected to
EMSA as described previously [43]. For supershift assays,
DNA:protein complexes were incubated with antibodies
for ten minutes before electrophoresis. An antibody
against p65 was from Millipore Corporation (Billerica,
MA, USA), whereas p50 and p52 antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). DNA
binding activities of Oct-1 and SP-1 in these extracts
were measured as controls. All oligonucleotide probe
DNAs were purchased from Promega Corporation
(Madison, Wisconsin, USA).
Flow cytometric sorting of CD44+/CD24- and CD44-/CD24
+ MCF-10A cells and additional flow cytometry analyses
Cells were incubated with FITC conjugated CD44 and
PE conjugated CD24 antibodies (BD Biosciences, San
Jose, CA, Catalogue number 555478 and 558428, respec-
tively) as described previously [21]. Cells were sorted by
flow cytometry and sorted cells were grown in culture
for three days before RNA preparation. The same anti-
bodies were used for characterizing cells under different
treatment conditions. Note that all flow cytometry data
presented here included isotype controls, individual anti-
body, and combination of antibodies. To conserve space,
data from CD44 and CD24 antibody combination only
are presented in some figures.
Microarray analysis
For each experimental condition, four independent sam-
ples of total RNA were prepared using RNAeasy kits
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. Microarray hybridization using Affy-
metric Human Genome HG 133 plus 2 GeneChip and
statistical analysis was performed as previously described
[44]. Briefly, data were extracted using the MicroArray
Suite 5 (MAS5) algorithm and exported into MicroArray
Data Portal for analysis and linking to bioinformatics
resources. Prior to analysis, probe sets that were not
called present in at least half of the arrays in at least
one experimental condition were removed; this proce-
dure reduced the number of false positives. The MAS5
signals (expression values) were log transformed, and
differences in gene expression between CD44+/CD24-
and CD44-/CD24+ cells were identified by Welch’s
t-tests. The gene expression array data have been sub-
mitted to the Gene Expression Omnibus (GEO) data-
base http://www.ncbi.nlm.nih.gov/geo/ under the
accession number GSE15192.
Reverse transcription polymerase chain reaction (RT-PCR)
The one step RT-PCR kit from Invitrogen Corporation
(Carlsbad, CA, USA) was used to perform RT-PCR
according to the manufacturer’si n s t r u c t i o n s .R T - P C R
(Usually at 60°C annealing and 72°C amplification)
cycles varied between primer sets to ensure that amplifi-
cation has not reached saturation level. Quantitative
RT-PCR using SyberGreen on a TaqMan 7900HT
instrument (Applied Biosystems, Carlsbad, CA, USA)
was performed according to the manufacturer’s instruc-
tions in order to measure SLUG expression in MCF-
10A cells. Additional file 1, Table S1 contains the
primer sequences used.
Antibodies and Western blot analysis
Antibodies against E-cadherin (BD Biosciences), N-cad-
herin (Cell Signaling Technologies, Danvers, MA, USA),
vimentin (Sigma, St. Louis, MO, USA), alpha smooth
muscle actin (aSMA) (Sigma), and beta-actin (Sigma)
were used for western blot analyses as per instructions
from manufacturers. Cell lysate preparations in radioim-
munoassay buffer and blotting conditions have been
described previously [40].
Cell proliferation assay
Cell proliferation assays were performed in 96-well
plates and rate of proliferation was measured using bro-
modeoxyuridine-ELISA assay (EMD Biosciences, San
Diego, CA, USA). One thousand cells were plated on
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four and six.
Results
Significant gene expression differences between the
CD44+/CD24- and CD44-/CD24+ subpopulations of
MCF-10A cells
MCF-10A cells were originally isolated from fibrocystic
disease and are believed to contain stem/basal/myoe-
pithelial cells [39,45,46]. Depending on confluency of
plating, a subpopulation of these cells spontaneously
acquires CD44+/CD24- phenotype [47]. Three distinct
subpopulations could be detected with these cells;
CD44+/CD24-, CD44+/CD24+, and CD44-/CD24+
(Figure 1A). Isolated CD44+/CD24- MCF-10A cells
displayed a density dependent growth rate: growth was
slower than CD44-/CD24+ cells in 100 mm plates
(Figure 1B) but faster in 96 well plates compared to
unsorted, CD44-/CD24+ or CD44+/CD24+ cells under
same growth conditions (Figure 1C). In general, CD44
+/CD24+ cells were difficult to grow; therefore, only a
limited number of studies were performed with these
cells. In matrigel, CD44+/CD24- cells formed larger
acini compared to CD44-/CD24+ cells (Figure 1B).
To determine the differential gene expression pattern
in CD44+/CD24- and CD44-/CD24+ cells of this
immortalized but not transformed cell line we per-
formed microarray analysis. The analysis was performed
in quadruplicate. Two thousand thirty five genes were
expressed differentially between the two cell types when
the expression differential had a p < 0.001 (Welch’s
t-test), a fraction of at least 0.5 and an absolute expres-
sion level difference of ≥ 2-fold (Additional file 2, Table
S2). Among them, 1145 genes showed relatively
increased expression in CD44+/CD24- cells. For exam-
ple, the expression of lumican and connexin-43 were
higher by more than 350-fold in CD44+/CD24- cells
compared to CD44-/CD24+ cells. In contrast, CD44-/
CD24+ cells expressed more than 100-fold higher levels
of several members of kallikrein family (5, 7 and 10),
E-cadherin, and P-cadherin. CD44+/CD24- cells
expressed 16-fold lower levels of claudin; breast epithe-
lial cells expressing lower levels of claudin display primi-
tive stem cell characteristics (CD49f
hiEpCAM-ER-PR-
HER2-CD24-CD133
lo) [20]. Therefore, the CD44
+/CD24- subpopulation of MCF-10A cells used in this
study may be the stem cell source that primarily main-
tains the cell line.
The number of genes that we observed to be differen-
tially expressed was significantly higher than the number
of differentially expressed genes obtained with purified
normal or cancerous CD44+ and CD24+ cells from pri-
mary tissues in other studies. For example, with a
Figure 1 Growth properties of the CD44+/CD24- and CD44-/
CD24+ subpopulations of MCF-10A cells. A) Flow cytometric
analysis of MCF-10A cells labeled with CD44-FITC and CD24-PE
antibodies. Total MCF-10A cells can be divided into three distinct
subpopulations: CD44+/CD24-, CD44-/CD24+, and CD44+/CD24+. B)
Representative growth characteristics of CD44+/CD24- and CD44-/
CD24+ cells in 2 D culture (top panel) and 3D-matrigel cultures.
Hematoxylin & Eosin staining was performed to characterize cells
grown in matrigel. C) Proliferation rate of CD44+/CD24-, CD44-/
CD24+, and CD44+/CD24+ cells. Proliferation rate was measured
using bromodeoxyuridine incorporation assay. Representative data
from two experiments, both done in duplicate with eight wells per
cell type, are shown.
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expression of 1114 and 1207 genes between CD44+ and
CD24+ cells of normal breast and cancer, respectively
[19]. Liu et al observed differential expression of 186
genes in tumorigenic CD44+/CD24- compared to nor-
mal breast epithelium [13]. Furthermore, the number of
genes identified in our study is significantly higher than
the number of genes identified as differentially expressed
in MCF-10A cells undergoing spontaneous EMT due to
differences in confluency [47]. These differences could
be related to the relative homogeneity of our cells com-
pared to cells obtained from normal breast or breast
cancers. Nonetheless, we found a significant overlap in
genes that were identified in our study with that of Shi-
pitsin et al [19]. For example, PROCR, which was
described as an additional marker of CD44+/CD24-
cells, is highly expressed in the CD44+/CD24- fraction
of MCF-10A cells. We also found increased expression
of interleukin 8 (IL-8) in CD44+/CD24- cells compared
to CD44-/CD24+ cells (Table 1). IL-8 has recently been
shown to increase the proportion of CSCs with mam-
mosphere forming ability [48].
Validation of select differentially expressed genes
To validate differentially expressed genes in different
subpopulation of cells, we performed western blot and
RT-PCR analysis. Some of the assays were done with
two independent samples (indicated as 1 and 2 in Figure
2A). In western blot analysis, we observed elevated
expression of ST-2 (IL-1RL1) in CD44+/CD24- cells
compared to CD44-/CD24+ cells (Figure 2A, left panel);
this gene was elevated in CD44+/CD24- cells by 64-fold
at mRNA level (Additional file 2, Table S2). There was a
modest increase in integrin beta 1 (CD61) in CD44
+/CD24- cells compared to CD44-/CD24+ cells. In
contrast, CD44+/CD24- cells expressed very little
Table 1 EMT-associated genes overexpressed in CD44+/CD24- cells compared to CD44-/CD24+ cells
Gene Symbol Gene name GenBank number Fold- change
AKT3 V-AKT murine thymoma oncogene homolog 3 NM_005465 2.0
BDNF Brain-derived neurotropic factor NM_001709 28.8
CDH2 Cadherin-2 (N-cadherin) NM_001792 29.8
CTGF Connective tissue growth factor NM_001901 33.5
DAB2 Disabled homolog 2 NM_001343 2.4
FGFR1 Fibroblast growth factor receptor 1 NM_023105 2.6
FYN FYN oncogene related to SRC, FGR, YES NM_002037 10.1
HMGA2 High mobility AT-hook 2 NM_003483 24.4
IL8 Interleukin 8 NM_000584 4.8
ILK Integrin-linked kinase NM_004517 2.1
ITF2/TCF4 Transcription factor 4 NM_003199 2.1
JAG1 Jagged 1 NM_000214 2.6
JAK2 Janus kinase 2 NM_004972 2.0
MAP4K4 Mitogen activated protein kinase kinase kinase kinase NM_017792 2.0
MMP-2 Matrix metalloproteinase 2 NM_004530 14.5
NR2F1/COUP-TF1 Nuclear receptor subfamily 2, group F, member 1 NM_005654 17.9
Periostin Periostin, osteoblast specific factor NM_006475 81.7
PIK3R1 PI3 kinase regulatory subunit (p85) NM_181523 2.7
PRKC alpha Protein kinase C alpha NM_002737 6.8
S100A4 S100, calcium binding protein A4 NM_002961 7.0
SMAD3 SMAD, mother against DPP homolog 3 NM_005902 2.0
SMAD7 SMAD, mother against DPP homolog 7 NM_005904 3.4
SMURF2 SMAD-specific E3 ubiquitin ligase 2 NM_022739 2.1
SNAI2/SLUG SNAIL homolog 2 NM_003068 2.3
SPARC Secreted protein cysteine-rich (osteonectin) NM_003118 107.7
TGFb1 Transforming growth factor beta 1 NM_011577 4.6
TGFb2 Transforming growth factor beta 2 NM_003238 3.4
TWIST2 TWIST homology 2 NM_057179 4.8
Wnt5A Wingless type, MMTV integration family member, type 5A NM_003392 6.9
Wnt5B Wingless type, MMTV integration family member, type 5B NM_030775 60.1
ZEB-1/TCF8 Transcription factor 8 NM_024285 27.8
ZEB-2/ZFHX1B Zinc finger E-box binding homeobox 2 NM_014795 8.3
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Page 5 of 16Figure 2 Western blot and RT-PCR analysis of genes differentially expressed in CD44+/CD24-, CD44-/CD24+ and CD44+/CD24+ cells.
A) CD44+/CD24- cells express higher levels of ST-2, N-cadherin, ETV5, FHL-1, Wnt5B, FOXC2, SATB-1, SLUG, and Gli-2, whereas CD44-/CD24+ cells
express higher levels of E-cadherin, ST14, ESE1, and KLK7. Western blotting or RT-PCR was performed to measure protein (left panel) or RNA
(central panel) from two independent samples (labeled 1 and 2). B) Cell lines with CD44+/CD24- subpopulation express higher levels of SLUG
and Gli-2. C) Expression levels of EMT markers and few additional genes in unsorted MCF-10A, CD44+/CD24-, CD44-/CD24+, and CD44+/CD24+
cells. RT-PCR was used to measure SLUG, Gli-2, ESE1, and Bmi-1, whereas western blotting was used to measure E-cadherin, N-cadherin, vimentin,
and aSMA.
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difference in E-cadherin (CDH1) expression at the
mRNA level between the two cell types was 192-fold
(Additional file 2, Table S2).
We confirmed differential expression of several other
genes by RT-PCR. For example, the expression of stem-
ness-associated genes was elevated in CD44+/CD24-
cells compared to CD44-/CD24+ cells (Figure 2A, central
and right panel). Specifically, we observed elevated
expression of N-cadherin, FOXC2, ETV5, Wnt5B, and
SLUG in CD44+/CD24- cells compared to CD44-/CD24
+ cells. In contrast to the above genes, ST14, ESE1, and
KLK7, which showed higher expression levels in CD44-/
CD24+ cells (> 140-fold) compared to CD44+/CD24-
cells in microarray (Additional file 2, Table S2), displayed
elevated expression in CD44-/CD24+ cells in RT-PCR
assay (Figure 2A, central panel).
Among genes that form a part of the transcription fac-
tor network in breast tissue stem cells [16], increased
expression of Gli-2 (downstream of Hedgehog) was
observed in CD44+/CD24- cells while Bmi-1 and Nanog
expression did not differ between CD44+/CD24- and
CD44-/CD24+ cells (Figure 2A, right panel). Analysis of
several breast cancer cell lines revealed the co-expres-
sion of Gli-2 and SLUG in only breast cancer cell lines
with CD44+/CD24- phenotype (Figure 2B). SATB-1 has
been recently described as a gene responsible for breast
cancer metastasis [49]. All SATB-1 expressing cell lines
used in that study were enriched for cells with the
CD44+/CD24- phenotype [21]. We observed elevated
expression of the SATB-1 gene in MCF-10A CD44
+/CD24- cells compared to CD44-/CD24+ cells by
microarray (Additional file 2, Table S2) and RT-PCR
(Figure 2A). However, unlike SLUG and Gli-2, SATB-1
is expressed in majority of cell lines tested and its
expression did not correlate with CD44+/CD24-
phenotype.
Expression levels of several of the genes noted above
were further examined in parental MCF-10A cells and
sorted CD44+/CD24-, CD44-/CD24+, and CD44+/CD24
+ subpopulations. SLUG and Gli-2 expression was high-
est in CD44+/CD24- cells followed by CD44+/CD24+
cells (Figure 2C). In contrast, ESE1 expression was high-
est in CD44-/CD24+ cells. CD44+/CD24- cells and to a
lesser extent CD44+/CD24+ cells displayed characteris-
tics of EMT by displaying lower levels of E-cadherin and
expressing elevated levels of N-cadherin, vimentin, and
aSMA compared to CD44-/CD24+ cells (Figure 2C,
bottom panel). These results further support the link
between EMT and the CD44+/CD24- phenotype. CD44
+/CD24+ cells appear to be of intermediate phenotype
expressing moderate levels of E-cadherin but yet expres-
sing N-cadherin and vimentin to a level similar to CD44
+/CD24- cells.
Genes differentially expressed in CD44+/CD24- cells are
part of specific signaling networks
We performed Ingenuity pathway analysis to identify
signaling networks that may be differentially active in
CD44+/CD24- and CD44-/CD24+ cells. Genes that are
upregulated in CD44+/CD24- cells are components of
five signaling networks: the follicular stimulating hor-
mone (FSH) signaling pathway; TNF/ERK/human chor-
ionic gonadotropin (HCG); p38/IFNa/PKc/JNK; NF-B/
AKT/PDGFb; and ESR1/BRCA1/CEBPb pathways
( A d d i t i o n a lf i l e s3 ,4 ,5 ,6 ,7 ,F i g u r e sS 1 - S 5 ) .G e n e st h a t
were downregulated in CD44+/CD24- cells compared to
CD44-/CD24+ cells are components of the FSH/HCG;
NF-B; ERK/p38 kinase; AP-2/GRB2/ZFP36; and
ERBB2/TGFb/RHO pathways (Additional files 8, 9, 10,
11, 12, Figures S6-S10).
Since EMT is linked to the CSC phenotype [37,38], we
compiled a list of EMT associated genes that exhibited
increased expression in CD44+/CD24- cells. Thirty-two
such EMT associated genes were identified (Table 1).
This list included most of the well-characterized EMT-
associated genes with the exception of SNAIL. Ingenuity
pathway analysis identified th e s eg e n e sa sp a r t i c i p a t i n g
in a network or networks comprising TGFb,N F - B,
connective tissue growth factor (CTGF), IL8, HCG, and
FSH (Figure 3A). Although a role for TGFb and IL8
pathways in the CSC phenotype is well known [19,48],
the significance of CTGF, HCG, and FSH pathways in
the CSC phenotype is unknown.
To confirm the differences in NF-B signaling path-
ways between CD44+/CD24, and CD44-/CD24+ cells,
we performed electrophoretic mobility shift assays
(EMSA) with lysates from these two cell types and
unsorted parental cells using a NF-B oligonucleotide
probe. NF-Be x i s t sa sa ni n a c t i v ec o m p l e xi nt h e
cytoplasm bound to IB proteins in unstimulated
cells. Stimulation of cells with cytokines such as TNF
release NF-Bf r o mI B to allow DNA binding [50].
CD44+/CD24- cells contained significantly higher
levels of NF-B:DNA complex compared to CD44-/
CD24+ cells or unsorted parental cells; antibody
supershift assay revealed the presence of p65 and p50
subunits of NF-B in this complex (Figure 3B).
CD44-/CD24+ cells acquire a CD44+/CD24- phenotype
upon overexpression of activated Ras or treatment with
tumor necrosis factor (TNF)
Results of the above analysis combined with the lack of
E-cadherin, and the increased expression of EMT-asso-
ciated genes in CD44+/CD24- MCF-10A cells suggested
ar o l ef o rT N Fa n dR a si ng e n e r a t i n gC D 4 4 + / C D 2 4 -
cells. TNF and Ras can activate a significant number of
the above noted pathways (p38, ERK, and NF-B in par-
ticular) in generating cells with CD44+/CD24-
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Page 7 of 16Figure 3 Signaling network involving CD44+/CD24-enriched EMT-associated genes. A) Ingenuity pathway analysis of EMT-associated genes
upregulated in CD44+/CD24- cells compared to CD44-/CD24+ cells. Genes in shaded shapes correspond to genes that are upregulated in CD44
+/CD24- cells compared to CD44-/CD24+ cells. B) NF-B:DNA complexes in unsorted MCF-10A, CD44+/CD24-, and CD44-/CD24+ subpopulation
of cells. CD44+/CD24- cells contained higher levels of p65:p50 heterodimers compared to other cell types. SS = supershift. EMSAs with Oct-1
and SP-1 probes are shown as controls.
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Page 8 of 16phenotype. Additionally, immune-induced EMT has
been shown to generate CSCs [5]. We have recently
s h o w nt h a tM C F - 1 0 Ac e l l su n d e r g oE M Tu p o ne x p o -
sure to TNF or overexpression of the constitutively
active NF-B subunit p65 [40]. P65 mediated EMT cor-
related with loss of E-cadherin and elevated expression
of ZEB-1 and ZEB-2 [40], both of which are expressed
at higher levels in CD44+/CD24- cells (Table 1).
Upon stable transfection of Ras oncogene or exposure
to TNF for 10 days, CD44-/CD24+ MCF-10A cells were
reanalyzed to assess their CD44 and CD24 phenotype.
In both cases, a fraction of cells became CD44+/CD24-
(Figure 4A). The effect of Ras in generating CD44
+/CD24- cells was accompanied with reduced expres-
sion of E-cadherin but not gain of vimentin, similar to a
previous report [37] (Figure 4B). The extent of TNF-
mediated CD44+/CD24- generation is similar to the
previously reported effects of TGFb1 [37] and is accom-
panied with reduction in E-cadherin expression and ele-
vated vimentin and aSMA expression. In mammosphere
Figure 4 Ras and TNF induce phenotype associated with cancer stem cells. A) The effects of Ras or p65 overexpression and TNF treatment
on CD44 and CD24 expression status in MCF-10A cells. Activated H-Ras oncogene or the constitutively active p65 subunit of NF-B was
overexpressed by retroviral vector mediated gene transfer. Expression level of Ras in MCF-10A-Ras cells as measured by western blotting is
shown (right panel, top) along with number of CD44+/CD24- cells in untreated and TNF treated MCF-10A cells from four experiments (p = 0.03,
right bottom panel). MCF-10A-p65 cells have already been described [40]. Cells were treated with 10 ng/ml of TNF for 10 days. B) The effect of
Ras overexpression or TNF treatment on the expression of EMT markers in MCF-10A cells. Ras reduced E-cadherin expression, whereas TNF
reduced E-cadherin but increased vimentin and aSMA. C) Assay demonstrating the effects of Ras overexpression on mammosphere formation.
Cells were plated for 10-days in mammosphere media. Ras increased both the number and the size of mammospheres.
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Page 9 of 16assay, Ras overexpressing cells showed an increase in
number as well as size of mammospheres (Figure 4C).
However, the effects of TNF on mammosphere forma-
tion both on numbers and size were not consistent, pos-
sibly due to issues related to half-life or access to
mammospheres in semi-solid growth media (data not
shown).
P65 altered the sorted cell phenotype from CD44-/
CD24+ to CD44+/CD24+ (Figure 4A). The effects of
p65 was much more dramatic than the effects of Ras
oncogene as more than 65% of cells acquired CD44
+/CD24+ phenotype. These results suggest that induced
EMT can change the surface expression pattern of
CD44 and CD24; however, specific changes are depen-
dent on the inducers of EMT. ZEB-1 and ZEB-2, which
are upregulated in MCF-10A cells overexpressing p65
[40], may only change CD44 but not CD24 expression
and thus result in a double positive phenotype.
Overexpression of SLUG, but not Gli-2 or SATB-1, leads to
changes in CD44 expression status in breast cancer cell
lines
A role for SNAIL and TWIST in the EMT-associated
increase in CD44+/CD24- has been demonstrated [38].
However, the possibility that SLUG participates in
CD44/CD24 phenotypic changes has not been investi-
gated, although its upregulation in basal breast cancers
and mammospheres has been reported recently [51].
Since our observation of increased SLUG expression in
CD44+/CD24- cells originated from a cell line study, we
f i r s te x a m i n e dt h eg e n ee x p r ession array data available
in NCBI GEO omnibus to correlate SLUG expression
with CD44+/CD24- status of primary breast cancers.
Previous comparative microarray analysis of CD44
+/CD24-/lineage- cancer cells and normal breast epithe-
lial cells revealed specific increased expression of SLUG
in the CD44+/CD24- subpopulation, although differ-
ences did not reach statistical significance due to small
sample size (3 samples for non-CD44 and five samples
for CD44+ tumor samples, p = 0.054) [13]. Additionally,
recent transcriptome analysis of mammary stem cells,
luminal progenitor cells, and mature luminal cells for
conserved genes between human and mouse in each of
these cell types revealed 3.16 fold elevated SLUG/SNAI2
expression in mammary stem cells compared to pro-
genitor or mature cells [52]. Thus, these independent
studies identify SLUG as a Stem/CD44+/CD24- cell
associated highly expressed gene. Based on its known
role in epigenetic regulation of gene expression through
recruitment of histone deacetylase complex [53] and
recent studies showing epigenetically controlled tran-
scription factors playing a key role in regulating the
mammary epithelial cell phenotype [54], SLUG appeared
as an ideal candidate to induce the CD44+/CD24-
phenotype. Since SLUG expression correlated with the
expression of Gli-2, and SATB-1 is highly expressed in
CD44+/CD24- MCF-10A cells, we examined the contri-
bution of these factors in inducing and/or maintaining
the CD44+/CD24- phenotype.
We overexpressed SLUG, Gli-2 and SATB-1 in two
cell lines: MCF-10A and MCF-7. Two independent mass
cultures of control vector or specific gene overexpres-
sing cells were analyzed. Since both clones had a similar
phenotype, results of one clone are presented in each
case. MCF-7 is an ERa-positive breast cancer cell line of
luminal subtype. For unknown reason, we were unable
to generate MCF-10A cells overexpressing SATB-1. The
expression levels of SLUG in control vector and SLUG
overexpressing cells are shown in Figure 5B. A subpopu-
lation of SLUG overexpressing MCF-10A cells displayed
the CD44+/CD24- phenotype (Figure 5C). Although we
used a bicistronic retrovirus and cells were selected
using a selectable marker, not all CD44-/CD24+ cells
acquired CD44+/CD24- phenotype. This suggests a
more dominant pathway may be involved in maintaining
the CD44-/CD24+ phenotype in MCF-10A cells. Alter-
natively, overexpression of SLUG may drive the acquisi-
tion of the CD44+/CD24- phenotype in a dose
dependent manner, or only in a subpopulation of
CD44-/CD24+ MCF-10A cells.
A subpopulation of MCF-7-SLUG cells acquired the
CD44+/CD24+ phenotype suggesting different effects of
SLUG on CD44 and CD24 expression in luminal and
basal cell types (Figure 5C). Although CD44+/CD24-
cells were originally described as CSCs, in the same ori-
ginal study, CD44+/CD24+ cancer cells isolated from
one patient with comedo (more aggressive) type adeno-
carcinoma were tumorigenic [10]. Therefore, it is possi-
ble that CSCs from luminal cell types may be different
than those from basal cell types and may be character-
ized as CD44+/CD24+.
We examined whether changes in CD44 and CD24
expression in SLUG overexpressing cells correlated
with altered expression of EMT-associated genes.
MCF-10A-SLUG cells displayed lower levels of E-cad-
herin but elevated vimentin compared to control vec-
tor-containing MCF10A-pQXIN cells (Figure 6A). In
contrast, MCF-7-SLUG cells showed no change in E-
cadherin expression but expressed vimentin compared
to MCF-7-pQXIN cells. Thus, SLUG overexpression
has cell type-specific effects on the expression of
EMT-associated genes. In a mammosphere assay,
MCF-7-SLUG cells formed more and larger mammo-
spheres compared to MCF-7-pQXIN cells, suggesting
SLUG may confer a CSC phenotype to luminal breast
cancer cells and these putative CSCs are phenotypically
CD44+/CD24+ (Figure 6B). MCF-10A-SLUG cells
appear to form larger mammospheres compared to
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Page 10 of 16Figure 5 SLUG overexpression leads to changes in CD44 and CD24 expression pattern. A) SLUG expression in CD44+/CD24- cells of
primary breast cancer compared to normal breast epithelium. These results were generated from the study in Ref 13 with a GEO accession
number GDS2617. B) RT-PCR (MCF-7 cells) or qRT-PCR (MCF-10A cells) analysis of overexpressed genes. C) Flow cytometric analysis of different
cell types for CD44 and CD24. A subpopulation of MCF-7-SLUG cells acquired the CD44+/CD24+ phenotype, whereas a subpopulation of MCF-
10A-SLUG cells acquired the CD44+/CD24- phenotype.
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Page 11 of 16MCF-10A-pQXIN cells; however, both cell types
formed similar number of mammospheres (Figure 6C).
In contrast to SLUG, Gli-2 overexpression did not
alter CD44 and CD24 status of either MCF-10A or
MCF-7 cells (Additional file 13, Figure S11A for the fig-
ure and Additional file 14 for the legend). Although
MCF-10A cells used for overexpression of Gli-2 were
initially sorted for CD44-/CD24+ cells, due to lower effi-
ciency of plasmid based transfection of Gli-2, selection
of transfected cells required longer time compared to
retroviral vector-based transduction of SLUG. Therefore,
some of the cells have spontaneously drifted to a CD44
+/CD24+ phenotype, which was similar between
pcDNA3 and Gli-2 transfected cells. MCF-7pcDNA3
and MCF-7-Gli-2 cells formed a similar number of
mammospheres; the size of mammospheres was also
similar (Additional file 13, Figure S11B). In addition,
Gli-2 overexpression in MCF-7 cells did not alter the
expression levels of E-cadherin, vimentin or a SMA
(Additional file 13, Figure S11C). Similar to Gli-2,
Figure 6 The effect of SLUG overexpression on the expression of EMT markers. MCF-10A-SLUG cells showed lower levels of E-cadherin
and higher levels of vimentin compared to MCF-10A-pQXIN cells. MCF-7-SLUG cells showed elevated vimentin compared to MCF-7-pQXIN cells.
B) Mammosphere forming ability of MCF-7pQXIN, MCF-7-SLUG, MCF-10A-pQXIN, and MCF-10A-SLUG cells. Mammospheres are shown on left,
whereas quantitative differences in number of mammospheres formed in two experiments are shown on right panel.
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Page 12 of 16SATB-1 did not change the CD44 and CD24 status of
MCF-7 cells (Additional file 13, Figure S11D). There-
fore, it appears that only SLUG is capable of inducing
the CD44+/CD24- phenotype in MCF-10A cells and the
CD44+/CD24+ phenotype in MCF-7 cells. However, we
cannot rule out that the different transgene delivery
method have played a part in the lack of effect from
Gli-2.
Discussion
In this report, we describe gene expression patterns in
the CD44+/CD24- and CD44-/CD24+ subpopulations of
MCF-10A cells. Unlike previous studies using similar
subpopulations of epithelial cells from normal or can-
cerous breast, our study identified a large number of
genes that are differentially expressed between cells with
these two phenotypes. This could be partly due to
MCF-10A cells being more homogenous, as well as not
having to amplify RNA before microarray analysis.
Based on the claudin expression pattern, CD44+/CD24-
cells that were used in this study appear to more closely
resemble stem cells [20]. Several of the genes upregu-
lated 10-fold or higher in CD44+/CD24- cells were cell
surface molecules, which can potentially be used to
further fractionate CD44+/CD24- cells into distinct sub-
populations and assayed for stem/progenitor status.
These molecules/markers include EPHA4, EPHA5, ST-
2, platelet growth factor receptor-like-1, LRP-1/CD91,
and Toll-like receptor 4.
Previous studies linking EMT to the CD44+/CD24-
phenotype identified only a few genes that may be
involved in generating CD44+/CD24- cells. These genes
included TWIST1, TWIST2, SNAIL, SLUG/SNAI2,
FOXC2, and ZFHX1B/ZEB-2 [38]. TWIST2, SLUG, and
ZEB-2 were also identified in our study to be elevated in
CD44+/CD24- cells (Table 1). We observed enhanced
expression in CD44+/CD24- cells of an additional 29
genes that have been associated with EMT. Pathway
analysis suggested that expression and/or activity of 27
of these genes are linked (Figure 3A). However, not all
genes involved in EMT are likely to have the ability to
induce the CD44+/CD24- phenotype. We had previously
demonstrated that MCF-10A cells overexpressing con-
stitutively active p65 undergo EMT, which is accompa-
nied by upregulation of ZEB-1 and ZEB-2 [40].
However, MCF-10A cells overexpressing p65 displayed a
CD44+/CD24+ phenotype, suggesting that ZEB-1 and
ZEB-2-mediated EMT did not involve generation of
CD44+/CD24- cells. Nonetheless, p65 overexpressing
CD44+/CD24+ cells may have stem cell like properties
similar to MCF-7-SLUG cells. In this respect, it has
recently been demonstrated that SRC-mediated transfor-
mation of MCF-10A cells involves the NF-B-Lin28B-
let7-IL-6 axis and this signaling axis generates cancer
cells with stem cell like properties [55]. Thus, it is likely
that cells with the CD44+/CD24- and CD44+/CD24+
phenotype have stem cell like properties at least based
on the mammosphere assay. Clinical prognostic studies
using CD44 and CD24 as markers may have to consider
both cell types. Since MCF-10A cells that have acquired
an EMT phenotype without co-expressing an oncogene
such as SRC and Ras or the cytokine IL-6 are not
tumorigenic [55], we did not characterize MCF-10A-
SLUG or MCF-10A-p65 cells in xenograft models for
CSC behavior.
Although SLUG was thought to function in a redun-
dant manner with SNAIL, several recent studies suggest
unique functions for SLUG. For the following reasons
SLUG appears to be much more relevant for generating
breast cancer cells with a CSC phenotype than SNAIL:
1) SLUG is downstream of Notch1 and Jagged 1 and is
essential for Notch1:Jagged 1 mediated EMT, tumor
growth, and metastasis [56]; 2) Jagged 1 expression in
primary breast cancer correlates with SLUG but not
SNAIL expression [56]; 3) SLUG expression correlates
with poor breast cancer prognosis [57]; 4) SLUG but
not SNAIL or TWIST is expressed in ES cells and is
part of the ES cell signature activated in several cancer
cells [58,59]; 5) SLUG contributes to the function of the
stem cell factor c-kit signaling pathways [60]; c-kit is
overexpressed in basal breast cancers, which are also
predominantly of CD44+/CD24- phenotype [21,61]; 6)
E-cadherin, whose experimental depletion in mammary
epithelial cells leads to generation of CSC-like cells [62],
represses SLUG but not SNAIL or TWIST expression
[56]; 7) SLUG is a potent repressor of the tumor sup-
pressor p53 and deregulation of p53 activity is often
observed in breast cancers [63]; 8) SLUG-/- embryonic
fibroblasts show reduced expression of several genes
linked to self-renewal and chromatin remodeling [64]; 9)
SLUG confers resistance to radiation, a characteristic of
CD44+/CD24- cells [65,66]; 10) SLUG but not SNAIL
expression, is linked to ductal development in the breast
including tubule maintenance or growth within invasive
ductal carcinoma [67]; and 11) SLUG is highly expressed
in basal type breast cancers, which also tend to express
higher levels of stem cell-associated genes [20,51,68].
These observations along with the results of this study
highlight critical role of SLUG in breast cancer.
Gli-2, a hedgehog pathway mediator linked to EMT
[69], failed to alter the CD44 and CD24 phenotype of
MCF-10A cells. This is somewhat surprising considering
previous reports showing elevated expression of Gli-2 in
primary mammary stem/progenitor cells and its associa-
tion with increased mammosphere-forming ability [16].
Overall our results raise two important issues: 1) not all
EMT associated genes can induce the CD44+/CD24-
phenotype when overexpressed; and 2) not all breast
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Page 13 of 16epithelial subtypes (luminal versus basal) acquire a sub-
population of cells with the CD44+/CD24- phenotype
upon overexpression of EMT-associated genes. In this
respect, our results agree with the observation that pri-
mary breast cancers expressing EMT markers are predo-
minantly of basal-like phenotype [47,51].
T h ea b i l i t yo fo n l yaf e wE M T - a s s o c i a t e dg e n e st o
induce the EMT phenotype and upregulate the expres-
sion of genes linked to the CD44+/CD24- phenotype
suggests that genes with this dual capacity have stronger
transcriptional activity, and in particular target chroma-
tin modifying genes. Several chromatin modifying genes
i n c l u d i n gH M G A 2 ,E P C 2 ,C B X 6 ,S M A R C A 1 ,a n d
SMARCA3 showed increased expression in CD44
+/CD24- cells (Additional file 2, Table S2). Future stu-
dies focusing on these genes may help to identify drugs
that target the CD44+/CD24- subpopulation of cancer
cells, as has been demonstrated recently using human
mammary epithelial cells depleted of E-cadherin or
overexpressing TWIST [62].
Conclusions
In this study, we have demonstrated increased expres-
sion of 32 EMT- associated genes in breast epithelial
cells with a CD44+/CD24- phenotype compared to
CD44-/CD24+ phenotype. Among these genes, SLUG
was able to convert CD44-/CD24+ cells to CD44
+/CD24- or CD44+/CD24+ cells, depending upon the
cell line. Treatment with TNF also could induce the
CD44+/CD24- phenotype, further supporting a role for
the microenvironment in generating cells with stem cell
phenotype.
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Additional file 1: Table 1: List of primers used for RT-PCR. This file
contains sequence of primers used for polymerase chain reactions.
Additional file 2: Table 2: List of genes differentially expressed in
CD44+/CD24- and CD44-/CD24+ subpopulation of MCF-10A cells.
This files contains list of genes that showed statistically significant
difference in expression (p < 0.001, ≥ 2-fold change) between CD44
+/CD24- and CD44-/CD24+ cells. Fold change in negative value
corresponds to genes expressed at higher levels in CD44+/CD24- cells
and in positive values corresponds to genes expressed at higher levels in
CD44-/CD24+ cells.
Additional file 3: Figure S1: Ingenuity pathway analysis of genes
expressed at higher levels in CD44+/CD24- cells. The majority of
genes in this pathway are linked to signaling by follicular stimulating
hormone (FSH). Shaded symbols indicate genes that are expressed at
higher levels.
Additional file 4: Figure S2: Ingenuity pathway analysis of genes
expressed at higher levels in CD44+/CD24- cells. The second
signaling network links highly expressed genes in CD44+/CD24- cells to
ERK and human chorionic gonadotropin (hCG) signaling.
Additional file 5: Figure S3: Ingenuity pathway analysis of genes
expressed at higher levels in CD44+/CD24- cells. The third signaling
network links highly expressed genes in CD44+/CD24- cells to p38, JNK
and interferon alpha.
Additional file 6: Figure S4: Ingenuity pathway analysis of genes
expressed at higher levels in CD44+/CD24- cells. The fourth signaling
pathway links highly expressed genes in CD44+/CD24- cells to NF-B.
Additional file 7: Figure S5: Ingenuity pathway analysis of genes
expressed at higher levels in CD44+/CD24- cells. The fifth signaling
pathway links highly expressed genes in CD44+/CD24- cells to BRCA1
and estrogen receptor (ESR1).
Additional file 8: Figure S6: Ingenuity pathway analysis of genes
expressed at lower levels in CD44+/CD24- cells compared to CD44-/
CD24+ cells. Genes in this network are linked to hCG and FSH
Additional file 9: Figure S7: Ingenuity pathway analysis of genes
expressed at lower levels in CD44+/CD24- cells compared to CD44-/
CD24+ cells. Genes in this network are linked to NF-B and IL-12
Additional file 10: Figure S8: Ingenuity pathway analysis of genes
expressed at lower levels in CD44+/CD24- cells compared to CD44-/
CD24+ cells. Genes in this network are linked to PI3 kinase/AKT
Additional file 11: Figure S9: Ingenuity pathway analysis of genes
expressed at lower levels in CD44+/CD24- cells compared to CD44-/
CD24+ cells. Genes in this network are linked to multiple signaling
molecules including growth hormone (GH1) and GRB2.
Additional file 12: Figure S10: Ingenuity pathway analysis of genes
expressed at lower levels in CD44+/CD24- cells compared to CD44-/
CD24+ cells. Genes in this network are linked to ERBB2 and TGFb1.
Additional file 13: Figure S11: The effect of Gli-2 and SATB1
overexpression on CD44 and CD24 cell surface expression. This
figure shows the inability of Gli-2 and SATB-1 to alter cell surface CD44
and CD24 expression profile, mammosphere formation, and EMT-
associated gene expression.
Additional file 14: Legend for figures and table in additional files.
This file provides detailed legend for all figures and tables, particularly
Figure S11.
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